FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseaseThe FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new Share XFDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseasehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease/
Boehringer, Lilly start acute heart failure trial with JardianceBoehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, Share XBoehringer, Lilly start acute heart failure trial with Jardiancehttps://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/
Diabetes drug Jardiance gains landmark cardiovascular approvalLilly and Boehringer Ingelheim will now be able to promote their drug Jardiance in the US as a Share XDiabetes drug Jardiance gains landmark cardiovascular approvalhttps://pharmaphorum.com/news/jardiancecvapproval/
New drugs boost Lilly in Q1 as company hopes for turnaround yearNew drugs from Eli Lilly have produced a strong showing in the first quarter, in what could be Share XNew drugs boost Lilly in Q1 as company hopes for turnaround yearhttps://pharmaphorum.com/transversal-categories/sales-and-marketing/new-drugs-boost-lilly-as-company-hopes-for-turnaround-year/
